BPMC

Blueprint Medicines (BPMC)

Blueprint Medicines Corporation

から:

Regulatory News

Text Search:

次の項目別のソート:

Non-Regulatory News

Showing the most relevant articles for your search:NASDAQ:BPMC

<< 前へ 1 2 3 4 5 6 7 8 9 10 11 12 13 14 次へ >>

日付	受信時刻	ニュースソース	見出し	コード	企業名
2023/06/08	08 : 53	Edgar (US Regulatory)	Statement of Changes in Beneficial Ownership (4)	NASDAQ:BPMC	Blueprint Medicines Corporation
2023/06/08	08 : 49	Edgar (US Regulatory)	Statement of Changes in Beneficial Ownership (4)	NASDAQ:BPMC	Blueprint Medicines Corporation
2023/06/06	06 : 00	PR Newswire (US)	Blueprint Medicines Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	NASDAQ:BPMC	Blueprint Medicines Corporation
2023/06/03	22 : 00	PR Newswire (US)	Blueprint Medicines Highlights Clinical Progress Across Precision Oncology Pipeline at 2023 ASCO Annual Meeting	NASDAQ:BPMC	Blueprint Medicines Corporation
2023/05/23	23 : 00	PR Newswire (US)	NEJM Evidence Publishes Results from Registrational PIONEER Trial Demonstrating Significant Clinical Benefits of AYVAKIT® (avapritinib) in Patients with Indolent Systemic Mastocytosis	NASDAQ:BPMC	Blueprint Medicines Corporation
2023/05/23	06 : 27	Dow Jones News	Blueprint Medicines Gets FDA Approval for Ayvakit	NASDAQ:BPMC	Blueprint Medicines Corporation
2023/05/23	05 : 54	Edgar (US Regulatory)	Current Report Filing (8-k)	NASDAQ:BPMC	Blueprint Medicines Corporation
2023/05/23	05 : 04	PR Newswire (US)	FDA Approves AYVAKIT® (avapritinib) as the First and Only Treatment for Indolent Systemic Mastocytosis	NASDAQ:BPMC	Blueprint Medicines Corporation
2023/05/11	06 : 02	Edgar (US Regulatory)	Ammended Annual Report to Security Holders (ars/a)	NASDAQ:BPMC	Blueprint Medicines Corporation
2023/05/05	06 : 01	PR Newswire (US)	Blueprint Medicines Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	NASDAQ:BPMC	Blueprint Medicines Corporation
2023/05/04	20 : 19	Edgar (US Regulatory)	Current Report Filing (8-k)	NASDAQ:BPMC	Blueprint Medicines Corporation
2023/05/04	20 : 00	PR Newswire (US)	Blueprint Medicines Reports First Quarter 2023 Results	NASDAQ:BPMC	Blueprint Medicines Corporation
2023/05/01	19 : 04	Edgar (US Regulatory)	Annual Report to Security Holders (ars)	NASDAQ:BPMC	Blueprint Medicines Corporation
2023/04/29	06 : 35	Edgar (US Regulatory)	Proxy Statement (definitive) (def 14a)	NASDAQ:BPMC	Blueprint Medicines Corporation
2023/04/26	23 : 00	PR Newswire (US)	Blueprint Medicines to Present New Clinical Data Across Broad Precision Therapy Pipeline at 2023 ASCO Annual Meeting	NASDAQ:BPMC	Blueprint Medicines Corporation
2023/04/21	05 : 01	PR Newswire (US)	Blueprint Medicines to Report First Quarter 2023 Financial Results on Thursday, May 4, 2023	NASDAQ:BPMC	Blueprint Medicines Corporation
2023/04/11	21 : 00	PR Newswire (US)	Blueprint Medicines to Present at Upcoming Investor Conferences	NASDAQ:BPMC	Blueprint Medicines Corporation
2023/04/06	05 : 01	PR Newswire (US)	Blueprint Medicines Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	NASDAQ:BPMC	Blueprint Medicines Corporation
2023/03/29	06 : 05	Edgar (US Regulatory)	Current Report Filing (8-k)	NASDAQ:BPMC	Blueprint Medicines Corporation
2023/03/29	05 : 05	PR Newswire (US)	Blueprint Medicines Announces Lift of Partial Clinical Hold on Phase 1/2 VELA Trial of BLU-222	NASDAQ:BPMC	Blueprint Medicines Corporation
2023/03/08	06 : 01	PR Newswire (US)	Blueprint Medicines Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	NASDAQ:BPMC	Blueprint Medicines Corporation
2023/02/27	05 : 00	PR Newswire (US)	Blueprint Medicines Presents Registrational Data from PIONEER Trial of AYVAKIT® (avapritinib) in Patients with Indolent Systemic Mastocytosis at 2023 AAAAI Annual Meeting	NASDAQ:BPMC	Blueprint Medicines Corporation
2023/02/24	06 : 07	Edgar (US Regulatory)	Current Report Filing (8-k)	NASDAQ:BPMC	Blueprint Medicines Corporation
2023/02/23	22 : 00	PR Newswire (US)	Blueprint Medicines to Regain Global Rights to GAVRETO® (pralsetinib) from Roche	NASDAQ:BPMC	Blueprint Medicines Corporation
2023/02/17	22 : 13	Edgar (US Regulatory)	Securities Registration: Employee Benefit Plan (s-8)	NASDAQ:BPMC	Blueprint Medicines Corporation
2023/02/17	22 : 08	Edgar (US Regulatory)	Prospectus Filed Pursuant to Rule 424(b)(5) (424b5)	NASDAQ:BPMC	Blueprint Medicines Corporation
2023/02/17	21 : 38	Edgar (US Regulatory)	Automatic Shelf Registration Statement of Securities of Well-known Seasoned Issuers (s-3asr)	NASDAQ:BPMC	Blueprint Medicines Corporation
2023/02/17	07 : 26	Edgar (US Regulatory)	Annual Report (10-k)	NASDAQ:BPMC	Blueprint Medicines Corporation
2023/02/16	22 : 22	Edgar (US Regulatory)	Current Report Filing (8-k)	NASDAQ:BPMC	Blueprint Medicines Corporation
2023/02/16	21 : 00	PR Newswire (US)	Blueprint Medicines Reports Fourth Quarter and Full Year 2022 Results	NASDAQ:BPMC	Blueprint Medicines Corporation